Market Research Logo

Sarcopenia - Pipeline Review, H2 2018

Sarcopenia - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H2 2018, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body’s ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sarcopenia (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sarcopenia (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sarcopenia (Musculoskeletal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sarcopenia (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sarcopenia (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Sarcopenia - Overview
Sarcopenia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Sarcopenia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sarcopenia - Companies Involved in Therapeutics Development
Amgen Inc
Biophytis SA
Faraday Pharmaceuticals Inc
GlaxoSmithKline Plc
Immusoft Corp
MYOS RENS Technology Inc
Neurotune AG
Novartis AG
Regeneron Pharmaceuticals Inc
ST Pharm Co., Ltd.
Teijin Pharma Ltd
Sarcopenia - Drug Profiles
ARM-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATA-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimagrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Muscle Wasting Disorders and Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVFA-829 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit SARM1 for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-1654 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclooxygenase 2 for Sarcopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Furin for Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium iodide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEISARM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sarcopenia - Dormant Projects
Sarcopenia - Product Development Milestones
Featured News & Press Releases
May 24, 2018: BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia
Mar 01, 2018: BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami
Dec 08, 2017: Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD)
Dec 04, 2017: Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium
Oct 30, 2017: BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia
Sep 25, 2017: Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia
May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia
May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial
Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
Mar 21, 2017: BIOPHYTIS to present on BIO101 at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Barcelona
Mar 01, 2017: BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos good pharmacokinetic profile in elderly patients
Dec 16, 2016: Biophytis presents preliminary clinical data of SARA - PK, and new preclinical data of Sarconeos for treating sarcopenia
Nov 29, 2016: BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile
Nov 22, 2016: BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients
Nov 15, 2016: BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Sarcopenia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Sarcopenia - Pipeline by Amgen Inc, H2 2018
Sarcopenia - Pipeline by Biophytis SA, H2 2018
Sarcopenia - Pipeline by Faraday Pharmaceuticals Inc, H2 2018
Sarcopenia - Pipeline by GlaxoSmithKline Plc, H2 2018
Sarcopenia - Pipeline by Immusoft Corp, H2 2018
Sarcopenia - Pipeline by MYOS RENS Technology Inc, H2 2018
Sarcopenia - Pipeline by Neurotune AG, H2 2018
Sarcopenia - Pipeline by Novartis AG, H2 2018
Sarcopenia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Sarcopenia - Pipeline by ST Pharm Co., Ltd. , H2 2018
Sarcopenia - Pipeline by Teijin Pharma Ltd, H2 2018
Sarcopenia - Dormant Projects, H2 2018
List of Figures
Number of Products under Development for Sarcopenia, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report